Top

Pituitary

Published in:

22-07-2022 | Acromegaly

Determinants of skeletal fragility in acromegaly: a systematic review and meta-analysis

Authors: Cláudia Ribeiro de Moura, Sara Campos Lopes, Ana Margarida Monteiro

Published in: Pituitary | Issue 6/2022

Abstract

Purpose

Vertebral fractures (VFs) are a potential complication in acromegaly. However, the etiology of this skeletal fragility is unknown. This review aimed to evaluate the effect of acromegaly on VFs, bone turnover, areal bone mineral density (aBMD), and bone quality/microarchitecture. The effect of disease activity and gonadal status in these determinants of skeletal fragility was also evaluated.

Methods

Articles published in English until September 6, 2020 on PubMed and Embase that reported at least one determinant of skeletal fragility in acromegalic patients, were included. Odds ratio (OR) to evaluate the risk of VFs and the standardized mean difference (SMD) to evaluate bone turnover, aBMD and bone quality/microarchitecture were calculated.

Results

Fifty-eight studies met eligibility criteria, assembling a total of 2412 acromegalic patients. Of these, 49 studies were included in the meta-analysis. Acromegalic patients, when compared to non-acromegalic patients, had higher risk of VFs [OR 7.00; 95% confidence interval (CI) 2.80–17.52; p < 0.0001], higher bone formation (SMD 1.14; 95% CI 0.69–1.59; p < 0.00001), higher bone resorption (SMD 0.60; 95% CI 0.09–1.10; p = 0.02) and higher aBMD at the femoral neck (SMD 0.36; 95% CI 0.15–0.57; p = 0.0009). No significant differences were found regarding aBMD at lumbar spine. Considering the results of the different techniques evaluating bone quality/microarchitecture, the main reported alterations were a decrease in trabecular bone thickness and density, and an increase in trabecular separation. The presence of active disease and/or hypogonadism were associated with worst results.

Conclusion

Patients with acromegaly are at increased risk of VFs, mainly because of deterioration in bone microarchitecture.

Available only for authorised users

Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951. https://doi.org/10.1210/jc.2014-2700CrossRefPubMed

Vilar L, Vilar CF, Lyra R, Lyra R, Naves LA (2017) Acromegaly: clinical features at diagnosis. Pituitary 20(1):22–32. https://doi.org/10.1007/s11102-016-0772-8CrossRefPubMed

Wassenaar MJE, Biermasz NR, Hamdy NAT, Zillikens MC, Van Meurs JBJ, Rivadeneira F et al (2011) High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur J Endocrinol 164(4):475–483. https://doi.org/10.1530/EJE-10-1005CrossRefPubMed

Mazziotti G, Bianchi A, Bonadonna S, Cimino V, Patelli I, Fusco A et al (2008) Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab 93(12):4649–4655. https://doi.org/10.1210/jc.2008-0791CrossRefPubMed

Giustina A, Mazziotti G, Canalis E (2008) Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29(5):535–559. https://doi.org/10.1210/er.2007-0036CrossRefPubMedPubMedCentral

Zgliczynski W, Kochman M, Misiorowski W, Zdunowski P (2007) In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and gender. Neuroendocrinol Lett 28(5):621–628PubMed

Eller-Vainicher C, Falchetti A, Gennari L, Cairoli E, Bertoldo F, Vescini F et al (2019) Diagnosis of endocrine disease: evaluation of bone fragility in endocrine disorders. Eur J Endocrinol 180(6):R213–R232. https://doi.org/10.1530/EJE-18-0991CrossRef

Kaji H, Sugimoto T, Nakaoka D, Okimura Y, Kaji H, Abe H et al (2001) Bone metabolism and body composition in Japanese patients with active acromegaly. Clin Endocrinol (Oxf) 55(2):175–181. https://doi.org/10.1046/j.1365-2265.2001.01280.xCrossRef

Giustina A (2020) Acromegaly and vertebral fractures: facts and questions. Trends Endocrinol Metab 31(4):274–275. https://doi.org/10.1016/j.tem.2020.01.011CrossRefPubMed

10.

Mazziotti G, Frara S, Giustina A (2018) Pituitary diseases and bone. Endocr Rev 39(4):440–488. https://doi.org/10.1210/er.2018-00005CrossRefPubMed

11.

Liu YL, Hsu JT, Shih TY, Luzhbin D, Tu CY, Wu J (2018) Quantification of volumetric bone mineral density of proximal femurs using a two-compartment model and computed tomography images. Biomed Res Int. https://doi.org/10.1155/2018/6284269CrossRefPubMedPubMedCentral

12.

Kužma M, Killinger Z, Jackuliak P, Vaòuga P, Hans D, Binkley N et al (2019) Pathophysiology of growth hormone secretion disorders and their impact on bone microstructure as measured by trabecular bone score. Physiol Res 68:121–129. https://doi.org/10.33549/physiolres.934303CrossRef

13.

Higgins J, Thompson S, Deeks J, Altman D (2003) Measuring inconsistency in meta-analyses. BMJ 327(7412):557–560. https://doi.org/10.1136/bmj.327.7414.557CrossRefPubMedPubMedCentral

14.

Higgins J, Li T, Deeks J (2020) Chapter 6—choosing effect measures and computing estimates of effects. Cochrane. https://training.cochrane.org/handbook/current/chapter-06. Accessed 20 July 2020

15.

Brozek JL, Akl EA, Alonso-Coello P, Lang D, Jaeschke R, Williams JW, Phillips B, Lelgemann M, Lethaby A, Bousquet J, Guyatt GH, Schünemann HJ, GRADE Working Group (2009) Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy 64(5):669–677. https://doi.org/10.1111/j.1398-9995.2009.01973.xCrossRefPubMed

16.

Štěpán J, Marek J, Havránek T, Doležal V, Pacovský V (1979) Bone isoenzyme of serum alkaline phosphatase in acromegaly. Clin Chim Acta 93(3):355–363. https://doi.org/10.1016/0009-8981(79)90285-7CrossRefPubMed

17.

de la Piedra C, Larrañaga J, Castro N, Horcajada C, Rapado A, Herrera Pombo JL, Carbó E (1988) Correlation among plasma osteocalcin, growth hormone, and somatomedin C in acromegaly. Calcif Tissue Int 43(1):44–45. https://doi.org/10.1007/BF02555167CrossRefPubMed

18.

Diamond T, Nery L, Posen S (1989) Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Ann Intern Med 111(7):567–573. https://doi.org/10.7326/0003-4819-111-7-567CrossRefPubMed

19.

Ho PJ, Fig LM, Barkan AL, Shapiro B (1992) Bone mineral density of the axial skeleton in acromegaly. J Nucl Med 33(9):1608–1612PubMed

20.

Marazuela M, Astigarraga B, Tabuenca MJ, Estrada J, Marín F, Lucas T (1993) Serum bone Gla protein as a marker of bone turnover in acromegaly. Calcif Tissue Int 52(6):419–421. https://doi.org/10.1007/BF00571329CrossRefPubMed

21.

Legovini P, De Menis E, Doroldi C, Carteri A, Billeci D, Roiter I et al (1993) Parathormone levels during treatment of acromegaly with octreotide: one-year follow-up. Curr Ther Res 53(4):360–366. https://doi.org/10.1016/S0011-393X(05)80195-XCrossRef

22.

Kotzmann H, Bernecker P, Hübsch P, Pietschmann P, Woloszczuk W, Svoboda T et al (1993) Bone mineral density and parameters of bone metabolism in patients with acromegaly. J Bone Miner Res 8(4):459–465. https://doi.org/10.1002/jbmr.5650080410CrossRefPubMed

23.

Piovesan A, Terzolo M, Reimondo G, Pia A, Codegone A, Osella G et al (1994) Biochemical markers of bone and collagen turnover in acromegaly or Cushing’s syndrome. Horm Metab Res 26(5):234–237. https://doi.org/10.1055/s-2007-1001672CrossRefPubMed

24.

Scillitani A, Chiodini I, Carnevale V, Giannatempo GM, Frusciante V, Villella M et al (1997) Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients. J Bone Miner Res 12(10):1729–1736. https://doi.org/10.1359/jbmr.1997.12.10.1729CrossRefPubMed

25.

Longobardi S, Di Somma C, Di Rella F, Angelillo N, Ferone D, Colao A et al (1998) Bone mineral density and circulating cytokines in patients with acromegaly. J Endocrinol Investig 21(10):688–693. https://doi.org/10.1007/BF03350799CrossRef

26.

Bolanowski M, Wielgus W, Milewicz A, Marciniak R (2000) Axial bone mineral density in patients with acromegaly. Acad Radiol 7(8):592–594. https://doi.org/10.1016/s1076-6332(00)80573-5CrossRefPubMed

27.

Ueland T, Bollerslev J, Godang K, Müller F, Frøland SS, Aukrust P (2001) Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess—possible role in bone homeostasis. Eur J Endocrinol 145(6):685–690. https://doi.org/10.1530/eje.0.1450685CrossRefPubMed

28.

Minisola S, Dionisi S, Pacitti MT, Paglia F, Carnevale V, Scillitani A et al (2002) Gender differences in serum markers of bone resorption in healthy subjects and patients with disorders affecting bone. Osteoporos Int 13(2):171–175. https://doi.org/10.1007/s001980200009CrossRefPubMed

29.

Ueland T, Ebbesen EN, Thomsen JS, Mosekilde L, Brixen K, Flyvbjerg A et al (2002) Decreased trabecular bone biomechanical competence, apparent density, IGF-II and IGFBP-5 content in acromegaly. Eur J Clin Investig 32(2):122–128. https://doi.org/10.1046/j.1365-2362.2002.00944.xCrossRef

30.

Bolanowski M, Jȩdrzejuk D, Milewicz A, Arkowska A (2002) Quantitative ultrasound of the heel and some parameters of bone turnover in patients with acromegaly. Osteoporos Int 13(4):303–308. https://doi.org/10.1007/s001980200030CrossRefPubMed

31.

Scillitani A, Battista C, Chiodini I, Carnevale V, Fusilli S, Ciccarelli E et al (2003) Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status. Clin Endocrinol (Oxf) 58(6):725–731. https://doi.org/10.1046/j.1365-2265.2003.01777.xCrossRef

32.

Matsuyama J, Eshima N, Fukunaga T, Hori S, Kobayashi H, Isono M (2003) Various risks of osteoporosis in patients with pituitary adenomas. J Bone Miner Metab 21(2):91–97. https://doi.org/10.1007/s007740300015CrossRefPubMed

33.

Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ (2003) Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 88(12):5650–5655. https://doi.org/10.1210/jc.2003-030772CrossRefPubMed

34.

Tütüncü NB, Erbaş T (2004) Factors associated with bone metabolism in acromegalic patients: hypogonadism and female gender. Exp Clin Endocrinol Diabetes 112(6):328–332. https://doi.org/10.1055/s-2004-820913CrossRefPubMed

35.

Bonadonna S, Mazziotti G, Nuzzo M, Bianchi A, Fusco A, De Marinis L et al (2005) Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 20(10):1837–1844. https://doi.org/10.1359/JBMR.050603CrossRefPubMed

36.

Biermasz NR, Hamdy NAT, Pereira AM, Romijn JA, Roelfsema F (2005) Long-term maintenance of the anabolic effects of GH on the skeleton in successful treated patients with acromegaly. Eur J Endocrinol 152(1):53–60. https://doi.org/10.1530/eje.1.01820CrossRefPubMed

37.

Bolanowski M, Daroszewski J, Mȩdraś M, Zadrozna-Śliwka B (2006) Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function. J Bone Miner Metab 24(1):72–78. https://doi.org/10.1007/s00774-005-0649-9CrossRefPubMed

38.

White HD, Ahmad AM, Durham BH, Chandran S, Patwala A, Fraser WD et al (2006) Effect of active acromegaly and its treatment on parathyroid circadian rhythmicity and parathyroid target-organ sensitivity. J Clin Endocrinol Metab 91(3):913–919. https://doi.org/10.1210/jc.2005-1602CrossRefPubMed

39.

Ueland T, Fougner SL, Godang K, Schreiner T, Bollerslev J (2006) Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. Eur J Endocrinol 155(5):709–715. https://doi.org/10.1530/eje.1.02285CrossRefPubMed

40.

Bolanowski M, Pluskiewicz W, Adamczyk P, Daroszewski J (2006) Quantitative ultrasound at the hand phalanges in patients with acromegaly. Ultrasound Med Biol 32(2):191–195. https://doi.org/10.1016/j.ultrasmedbio.2005.10.003CrossRefPubMed

41.

Kastelan D, Dusek T, Kraljevic I, Polasek O, Perkovic Z, Kardum I et al (2007) Bone properties in patients with acromegaly: quantitative ultrasound of the heel. J Clin Densitom 10(3):327–331. https://doi.org/10.1016/j.jocd.2007.03.103CrossRefPubMed

42.

Sasaki M, Okazaki R, Inoue D, Nakashima M, Ide F, Nakaguchi H et al (2009) Preoperative elevated serum growth hormone is preventive of osteopenia in postsurgical patients with pituitary somatotroph adenomas: comparison with clinically nonfunctioning adenomas. Endocrinologist 19(5):208–210CrossRef

43.

Battista C, Chiodini I, Muscarella S, Guglielmi G, Mascia ML, Carnevale V et al (2009) Spinal volumetric trabecular bone mass in acromegalic patients: a longitudinal study. Clin Endocrinol (Oxf) 70(3):378–382. https://doi.org/10.1111/j.1365-2265.2008.03322.xCrossRef

44.

Sucunza Alfonso N, Barahona MJ, Resmini E, Fernández-Real JM, Ricart W, Farrerons J et al (2009) A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly. J Clin Endocrinol Metab 94(10):3889–3896. https://doi.org/10.1210/jc.2009-0474CrossRef

45.

Madeira M, Neto LV, De Lima GAB, Moreira RO, De Mendonça LMC, Gadelha MR et al (2010) Effects of GH-IGF-I excess and gonadal status on bone mineral density and body composition in patients with acromegaly. Osteoporos Int 21(12):2019–2025. https://doi.org/10.1007/s00198-009-1165-xCrossRefPubMed

46.

Padova G, Borzì G, Incorvaia L, Siciliano G, Migliorino V, Vetri M et al (2011) Prevalence of osteoporosis and vertebral fractures in acromegalic patients. Clin Cases Miner Bone Metab 8(3):37–43PubMedPubMedCentral

47.

Madeira M, Neto LV, De Paula Paranhos Neto F, Lima ICB, De Mendonça LMC, Gadelha MR et al (2013) Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab 98(4):1734–1741. https://doi.org/10.1210/jc.2012-4073CrossRefPubMed

48.

Madeira M, Neto LV, Torres CH, de Mendonça LMC, Gadelha MR, de Farias MLF (2013) Vertebral fracture assessment in acromegaly. J Clin Densitom 16(2):238–243. https://doi.org/10.1016/j.jocd.2012.06.002CrossRefPubMed

49.

Mazziotti G, Bianchi A, Porcelli T, Mormando M, Maffezzoni F, Cristiano A et al (2013) Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab 98(8):3402–3410. https://doi.org/10.1210/jc.2013-1460CrossRefPubMed

50.

Serinsöz H, Ertörer ME, Başcıl S, Bakıner O, Bozkırlı E, Tütüncü NB (2015) Low prevalence of periodontitis in acromegaly: growth hormone may exert a protective effect. Turkish J Endocrinol Metab 19(2):42–48CrossRef

51.

Maffezzoni F, Maddalo M, Frara S, Mezzone M, Zorza I, Baruffaldi F et al (2016) High-resolution-cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures. Endocrine 54(2):532–542. https://doi.org/10.1007/s12020-016-1078-3CrossRefPubMed

52.

Hong AR, Kim JH, Kim SW, Kim SY, Shin CS (2016) Trabecular bone score as a skeletal fragility index in acromegaly patients. Osteoporos Int 27(3):1123–1129. https://doi.org/10.1007/s00198-015-3344-2CrossRefPubMed

53.

Valassi E, Crespo I, Malouf J, Vilades D, Leta R, Llauger J et al (2016) Epicardial fat is a negative predictor of spine volumetric bone mineral density and trabecular bone score in acromegaly. Endocrine 53(3):860–864. https://doi.org/10.1007/s12020-016-0945-2CrossRefPubMed

54.

Tuzcu S, Durmaz A, Carlıoğlu A, Demircan Z, Tuzcu A, Beyaz C et al (2017) The effects of high serum growth hormone and IGF-1 levels on bone mineral density in acromegaly. Z Rheumatol 76(8):716–722. https://doi.org/10.1007/s00393-016-0171-6CrossRefPubMed

55.

Malgo F, Hamdy NAT, Papapoulos SE, Appelman-Dijkstra NM (2017) Bone material strength index as measured by impact microindentation is low in patients with fractures irrespective of fracture site. Osteoporos Int 28(8):2433–2437. https://doi.org/10.1007/s00198-017-4054-8CrossRefPubMedPubMedCentral

56.

Constantin T, Tangpricha V, Shah R, Oyesiku NM, Ioachimescu OC, Ritchie J et al (2017) Calcium and bone turnover markers in acromegaly: a prospective, controlled study. J Clin Endocrinol Metab 102(7):2416–2424. https://doi.org/10.1210/jc.2016-3693CrossRefPubMed

57.

Silva PPB, Amlashi FG, Yu EW, Pulaski-liebert KJ, Gerweck AV, Fazeli K et al (2017) Bone microarchitecture and estimated bone strength in men with active acromegaly. Eur J Endocrinol 177(5):409–420. https://doi.org/10.1530/EJE-17-0468CrossRefPubMed

58.

Chiloiro S, Mormando M, Bianchi A, Giampietro A, Milardi D, Bima C et al (2018) Prevalence of morphometric vertebral fractures in “difficult” patients with acromegaly with different biochemical outcomes after multimodal treatment. Endocrine 59(2):449–453. https://doi.org/10.1007/s12020-017-1391-5CrossRefPubMed

59.

Carbonare LD, Micheletti V, Cosaro E, Valenti MT, Mottes M, Francia G et al (2018) Bone histomorphometry in acromegaly patients with fragility vertebral fractures. Pituitary 21(1):56–64. https://doi.org/10.1007/s11102-017-0847-1CrossRef

60.

Valenti MT, Mottes M, Cheri S, Deiana M, Micheletti V, Cosaro E et al (2018) Runx2 overexpression compromises bone quality in acromegalic patients. Endocr Relat Cancer 25(3):269–277. https://doi.org/10.1530/ERC-17-0523CrossRefPubMed

61.

Ozer FF, Dagdelen S, Erbas T (2018) Relation of RANKL and OPG levels with bone resorption in patients with acromegaly and prolactinoma. Horm Metab Res 50(7):562–567. https://doi.org/10.1055/a-0630-1529CrossRefPubMed

62.

Qin L, Guo X, Gao L, Wang Z, Feng C, Deng K et al (2019) Preoperative and postoperative bone mineral density change and risk factor analysis in patients with a GH-secreting pituitary adenoma. Int J Endocrinol. https://doi.org/10.1155/2019/21012566CrossRefPubMedPubMedCentral

63.

Godang K, Lekva T, Normann KR, Olarescu NC, Øystese KAB, Kolnes A et al (2019) Hip structure analyses in acromegaly: decrease of cortical bone thickness after treatment: a longitudinal cohort study. JBMR Plus 3(12):e10240. https://doi.org/10.1002/jbm4.10240CrossRefPubMedPubMedCentral

64.

Kužma M, Vaňuga P, Ságova I, Pávai D, Jackuliak P, Killinger Z et al (2019) Non-invasive DXA-derived bone structure assessment of acromegaly patients: a cross-sectional study. Eur J Endocrinol 180(3):201–211. https://doi.org/10.1530/EJE-18-0881CrossRefPubMed

65.

Valassi E, García-Giralt N, Malouf J, Crespo I, Llauger J, Díez-Pérez A et al (2019) Circulating mir-103a-3p and mir-660-5p are associated with bone parameters in patients with controlled acromegaly. Endocr Connect 8(1):39–49. https://doi.org/10.1530/EC-18-0482CrossRefPubMed

66.

Chiloiro S, Giampietro A, Stefano F, Chiara B, Frederico D, Fleseriu M et al (2019) Effects of pegvisomant and pasireotide LAR on vertebral fractures in acromegaly resistant to first-generation SRLs. J Clin Endocrinol Metab 105(3):dgz054. https://doi.org/10.1210/clinem/dgz054CrossRef

67.

Pelsma ICM, Biermasz NR, Pereira AM, van Furth WR, Appelman-Dijkstra NM, Kloppenburg M et al (2020) Progression of vertebral fractures in long-term controlled acromegaly: a 9-year follow-up study. Eur J Endocrinol 183(4):427–437. https://doi.org/10.1530/EJE-20-0415CrossRefPubMed

68.

Zhang Y, Liu M, Chen H, Zhu K, Feng W, Zhu D et al (2020) Associations between circulating bone-derived hormones lipocalin 2, osteocalcin, and glucose metabolism in acromegaly. J Endocrinol Investig 43(9):1309–1316. https://doi.org/10.1007/s40618-020-01221-9CrossRef

69.

de Castro DO, de Azevedo BP, Dytz MG, Barbosa BA, Júnior AJ, Reggatieri NAT et al (2020) Entropy and uniformity as additional parameters to optimize the effectiveness of bone CT in the evaluation of acromegalic patients. Endocrine 69(2):368–376. https://doi.org/10.1007/s12020-020-02358-6CrossRef

70.

Mys K, Stockmans F, Vereecke E, van Lenthe GH (2017) Quantification of bone microstructure in the wrist using cone-beam computed tomography. Bone 2018(114):206–214. https://doi.org/10.1016/j.bone.2018.06.006CrossRef

71.

Parfitt AM (2002) Misconceptions (2): turnover is always higher in cancellous than in cortical bone. Bone 30(6):807–809. https://doi.org/10.1016/S8756-3282(02)00735-4CrossRefPubMed

72.

Claessen KMJA, Kroon HM, Pereira AM, Appelman-Dijkstra NM, Verstegen MJ, Kloppenburg M et al (2013) Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study. J Clin Endocrinol Metab 98(12):4808–4815. https://doi.org/10.1210/jc.2013-2695CrossRefPubMed

73.

Ott SM (2018) Cortical or trabecular bone: what’s the difference? Am J Nephrol 47(6):373–375. https://doi.org/10.1159/000489672CrossRefPubMed

74.

Wassenaar MJE, Biermasz NR, van Duinen N, van der Klaauw AA, Pereira AM, Roelfsena F et al (2009) High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with long-term cure of acromegaly: a case–control study. Eur J Endocrinol 160(3):357–365. https://doi.org/10.1530/EJE-08-0845CrossRefPubMed

75.

Eller-Vainicher C, Cairoli E, Zhukouskaya VV, Morelli V, Palmieri S, Scillitani A et al (2013) Prevalence of subclinical contributors to low bone mineral density and/or fragility fracture. Eur J Endocrinol 169(2):225–237. https://doi.org/10.1530/EJE-13-0102CrossRefPubMed

76.

Giustina A, Barkan A, Beckers A, Biermasz N, Biller B, Boguszewski C et al (2020) A consensus on the diagnosis and treatment of acromegaly comorbidities: an uptade. J Clin Endocrinol Metab 105(4):dgz096. https://doi.org/10.1210/clinem/dgz096CrossRefPubMed

77.

Mazziotti G, Battista C, Maffezzoni F, Chiloiro S, Ferrante E, Prencipe N et al (2020) Treatment of acromegalic osteopathy in real-life clinical practice: the BAAC (Bone Active Drugs in Acromegaly) Study. J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgaa363CrossRefPubMedPubMedCentral

78.

Hardy RS, Zhou H, Seibel MJ, Cooper MS (2018) Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy. Endocr Rev 39(5):519–548. https://doi.org/10.1210/er.2018-00097CrossRefPubMed

79.

Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros AL, Sosa E, Jervis P, Roldan P, Mendoza V, López-Félix B, Guinto G (2014) Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab 99:4438–4446. https://doi.org/10.1210/jc.2014-2670CrossRefPubMed

80.

Ceccato F, Lizzul L, Zilio M, Barbot M, Denaro L, Emanuelli E, Alessio L, Rolma G, Manara R, Saller A, Boscaro M, Scaroni C (2016) Medical treatment for acromegaly does not increase the risk of central adrenal insufficiency: a long-term follow-up study. Horm Metab Res 48(8):514–519CrossRefPubMed

81.

Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM (2009) ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 94:4216–4223. https://doi.org/10.1210/jc.2009-1097CrossRefPubMed

82.

Schulz J, Frey KR, Cooper MS et al (2016) Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency. Eur J Endocrinol 174(4):531–538. https://doi.org/10.1530/EJE-15-1096CrossRefPubMed

83.

Krzentowska-Korek A, Gołkowski F, Bałdys-Waligórska A, Hubalewska-Dydejczyk A (2011) Efficacy and complications of neurosurgical treatment of acromegaly. Pituitary 14:157–162. https://doi.org/10.1007/s11102-010-0273-0CrossRefPubMed

84.

Katznelson L (2010) Approach to the patient with persistent acromegaly after pituitary surgery. J Clin Endocrinol Metab 95:4114–4123. https://doi.org/10.1210/jc.2010-0670CrossRefPubMed

85.

Minniti G, Jaffrain-Rea ML, Esposito V, Santoro A, Moroni C, Lenzi J, Tamburrano G, Cassone R, Cantore G (2001) Surgical treatment and clinical outcome of GH-secreting adenomas in elderly patients. Acta Neurochir 143:1205–1211. https://doi.org/10.1007/s007010100015CrossRefPubMed

Title: Determinants of skeletal fragility in acromegaly: a systematic review and meta-analysis
Authors: Cláudia Ribeiro de Moura
Sara Campos Lopes
Ana Margarida Monteiro
Publication date: 22-07-2022
Publisher: Springer US
Keyword: Acromegaly
Published in: Pituitary / Issue 6/2022
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-022-01256-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2022

Influence of growth hormone therapy on germinoma survivors

Demonstration of the inferior intercavernous sinus is closely linked to the extent of pneumatization of the sphenoid sinus: useful information for the pituitary surgeon

Idiopathic central diabetes insipidus in a large cohort of patients: the hypopituitarism ENEA rare observational (HEROS) study

Changing the name of diabetes insipidus

Development of a cost-effective diagnostic algorithm incorporating transcription factor immunohistochemistry in the evaluation of pituitary tumours

Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage